Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches

Author(s): Darshan Bhirud, Gyan Agrawal, Harshil Shah, Artiben Patel, Mahesh B. Palkar, Sankha Bhattacharya* and Bhupendra G. Prajapati*

Volume 24, Issue 6, 2024

Published on: 06 February, 2024

Page: [503 - 522] Pages: 20

DOI: 10.2174/0115680266278636240125113509

Price: $65

Abstract

Since their discovery in valsartan-containing drugs, nitrosamine impurities have emerged as a significant safety problem in pharmaceutical products, prompting extensive recalls and suspensions. Valsartan, candesartan, irbesartan, olmesartan, and other sartans have been discovered to have additional nitrosamine impurities, such as N-nitroso-N-methyl-4-aminobutyric acid (NMBA), N-nitroso-Di-isopropyl amine (NDIPA), N-nitroso-Ethyl-Isopropyl amine (NEIPA), and N-nitroso-Diethyl amine (NDEA). Concerns about drug safety have grown in response to reports of nitrosamine contamination in pharmaceuticals, such as pioglitazone, rifampin, rifapentine, and varenicline. This review investigates the occurrence and impact of nitrosamine impurities in sartans and pharmaceutical goods, as well as their underlying causes. The discussion emphasizes the significance of comprehensive risk assessment and mitigation approaches at various phases of medication development and manufacturing. The link between amines and nitrosamine impurities is also investigated, with an emphasis on pH levels and the behaviour of primary, secondary, tertiary, and quaternary amines. Regulations defining standards for nitrosamine assessment and management, such as ICH Q3A-Q3E and ICH M7, are critical in resolving impurity issues. Furthermore, the Global Substance Registration System (GSRS) is underlined as being critical for information sharing and product safety in the pharmaceutical industry. The review specifically focuses on the relationship between ranitidine and N-nitroso dimethyl amine (NDMA) in the context of the implications of nitrosamine contamination on patient safety and medicine supply. The importance of regulatory authorities in discovering and correcting nitrosamine impurities is highlighted in order to improve patient safety, product quality, and life expectancy. Furthermore, the significance of ongoing study and attention to nitrosamine-related repercussions for increasing pharmaceutical safety and overall public health is emphasized.

Keywords: Nitrosamines, ICH Q3A-Q3E, Global Substance Registration System (GSRS), N-nitroso dimethyl amine (NDMA), Drug substance life cycle, FDA.

« Previous Next »
Graphical Abstract

[1]
Mansouri, I.; Botton, J.; Semenzato, L.; Haddy, N.; Zureik, M. N -nitrosodimethylamine-contaminated valsartan and risk of cancer: A nationwide study of 1.4 million valsartan users. J. Am. Heart Assoc., 2022, 11(24), e8067.
[http://dx.doi.org/10.1161/JAHA.122.026739] [PMID: 36533625]
[2]
Zhang, J.; Selaya, S.D.; Shakleya, D.; Mohammad, A.; Faustino, P.J. Rapid quantitation of four nitrosamine impurities in angiotensin receptor blocker drug substances. J. Pharm. Sci., 2023, 112(5), 1246-1254.
[http://dx.doi.org/10.1016/j.xphs.2022.12.005] [PMID: 36509171]
[3]
He, S.; Wei, J.; Ding, L.; Yang, X.; Wu, Y. State-of-the-arts techniques and current evolving approaches in the separation and detection of circulating tumor cell. Talanta, 2022, 239, 123024.
[http://dx.doi.org/10.1016/j.talanta.2021.123024] [PMID: 34952370]
[4]
Sokol, H.; Leducq, V.; Aschard, H.; Pham, H.P.; Jegou, S.; Landman, C.; Cohen, D.; Liguori, G.; Bourrier, A.; Nion-Larmurier, I.; Cosnes, J.; Seksik, P.; Langella, P.; Skurnik, D.; Richard, M.L.; Beaugerie, L. Fungal microbiota dysbiosis in IBD. Gut, 2017, 66(6), 1039-1048.
[http://dx.doi.org/10.1136/gutjnl-2015-310746] [PMID: 26843508]
[5]
Elder, D.P.; Johnson, G.E.; Snodin, D.J. Tolerability of risk: A commentary on the nitrosamine contamination issue. J. Pharm. Sci., 2021, 110(6), 2311-2328.
[http://dx.doi.org/10.1016/j.xphs.2021.02.028] [PMID: 33705731]
[6]
Giménez-Campillo, C.; Pastor-Belda, M.; Campillo, N.; Hernández-Córdoba, M.; Viñas, P. Development of a new methodology for the determination of N-nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometry. Talanta, 2021, 223(Pt 2), 121659.
[http://dx.doi.org/10.1016/j.talanta.2020.121659] [PMID: 33298254]
[7]
Kao, Y.T.; Wang, S.F.; Wu, M.H.; Her, S.H.; Yang, Y.H.; Lee, C.H.; Lee, H.F.; Lee, A.R.; Chang, L.C.; Pao, L.H. A substructure-based screening approach to uncover N-nitrosamines in drug substances. Yao Wu Shi Pin Fen Xi, 2022, 30(1), 150-162.
[http://dx.doi.org/10.38212/2224-6614.3400] [PMID: 35647726]
[8]
George, J.; Rao, K.R.; Stern, R.; Chandrakasan, G. Dimethylnitrosamine-induced liver injury in rats: The early deposition of collagen. Toxicology, 2001, 156(2-3), 129-138.
[http://dx.doi.org/10.1016/S0300-483X(00)00352-8] [PMID: 11164615]
[9]
Bharate, S.S. Critical analysis of drug product recalls due to nitrosamine impurities. J. Med. Chem., 2021, 64(6), 2923-2936.
[http://dx.doi.org/10.1021/acs.jmedchem.0c02120] [PMID: 33706513]
[10]
Charoo, N.A.; Ali, A.A.; Buha, S.K.; Rahman, Z. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech, 2019, 20(5), 166.
[http://dx.doi.org/10.1208/s12249-019-1376-1] [PMID: 30989447]
[11]
Wang, Q.; Liu, Z.; Liu, Y.; Chen, H. Absolute quantitation of N-nitrosamines by coulometric mass spectrometry without using standards. J. Am. Soc. Mass Spectrom., 2022, 33(5), 875-884.
[http://dx.doi.org/10.1021/jasms.2c00064] [PMID: 35446584]
[12]
Tuesuwan, B.; Vongsutilers, V. Nitrosamine contamination in pharmaceuticals: Threat, impact, and control. J. Pharm. Sci., 2021, 110(9), 3118-3128.
[http://dx.doi.org/10.1016/j.xphs.2021.04.021] [PMID: 33989680]
[13]
Witt, O.N. XXIII.—On aromatic nitrosamines. J. Chem. Soc. Trans., 1878, 33(0), 202-211.
[http://dx.doi.org/10.1039/CT8783300202]
[14]
Ashworth, I.W.; Dirat, O.; Teasdale, A.; Whiting, M. Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: An assessment of the risk posed by trace nitrite in water. Org. Process Res. Dev., 2020, 24(9), 1629-1646.
[http://dx.doi.org/10.1021/acs.oprd.0c00224]
[15]
Ashworth, I.W.; Curran, T.; Dirat, O.; Zheng, J.; Whiting, M.; Lee, D. A consideration of the extent that tertiary amines can form N -nitroso dialkylamines in pharmaceutical products. Org. Process Res. Dev., 2023, 27(10), 1714-1718.
[http://dx.doi.org/10.1021/acs.oprd.3c00073]
[16]
Engel, L.S.; Zabor, E.C.; Satagopan, J.; Widell, A.; Rothman, N.; O’Brien, T.R.; Zhang, M.; Van Den Eeden, S.K.; Grimsrud, T.K. Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case–control study nested within two prospective cohorts. Int. J. Cancer, 2019, 145(9), 2360-2371.
[http://dx.doi.org/10.1002/ijc.32175] [PMID: 30701531]
[17]
Zahra, N.; Saeed, M.K.; Raza, M.H. Nitrosamines: Incredibly unsafe contaminants in different food commodities. Chem. Int., 2023, 9(1), 27-36.
[18]
Beard, J.C.; Swager, T.M. An organic chemist’s guide to N-nitrosamines: Their structure, reactivity, and role as contaminants. J. Org. Chem., 2021, 86(3), 2037-2057.
[http://dx.doi.org/10.1021/acs.joc.0c02774] [PMID: 33474939]
[19]
Snodin, D.J. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines. Regul. Toxicol. Pharmacol., 2023, 141, 105403.
[http://dx.doi.org/10.1016/j.yrtph.2023.105403] [PMID: 37116739]
[20]
Kostal, J.; Voutchkova-Kostal, A. Quantum-mechanical approach to predicting the carcinogenic potency of N -nitroso impurities in pharmaceuticals. Chem. Res. Toxicol., 2023, 36(2), 291-304.
[http://dx.doi.org/10.1021/acs.chemrestox.2c00380] [PMID: 36745540]
[21]
Alsolais, A.M.; Althafar, Z.M.; Hasan, M.R.; Hakami, M.A.; Omar, B.I.A.; Hessien, K.B.G. Ranitidine contaminated with N-Nitrosodimethylamine (Ndma) link to carcinoma: A systematic review and meta-analysis. J. Pharm. Negat. Results, 2023, 14(2), 2031-2043.
[22]
Hoffmann, D.; Hoffmann, I.; El-Bayoumy, K. The less harmful cigarette: A controversial issue. a tribute to Ernst L. Wynder. Chem. Res. Toxicol., 2001, 14(7), 767-790.
[http://dx.doi.org/10.1021/tx000260u] [PMID: 11453723]
[23]
Balayiannis, G.P.; Karasali, H. N-nitrosamine impurities in ethalfluralin: Determination of an overlooked deleterious source in pesticides. Agriculture, 2023, 13(5), 1104.
[http://dx.doi.org/10.3390/agriculture13051104]
[24]
dos Santos, C.E.M.; Dorta, D.J.; de Oliveira, D.P. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities. Regul. Toxicol. Pharmacol., 2022, 136, 105288.
[http://dx.doi.org/10.1016/j.yrtph.2022.105288] [PMID: 36384172]
[25]
Ahirwar, P.; Khare, B.; Jain, P.K.; Jain, A.; Khan, R.; Thakur, B. compressive review on role of ICH guidelines in registration of pharmaceutical products. AJDHS, 2022, 2(3), 1-8.
[http://dx.doi.org/10.22270/ajdhs.v2i3.16]
[26]
Ojha, A.; Bhargava, S. International council for harmonisation (ICH) guidelines. In: Regulatory affairs in the pharmaceutical industry; Elsevier, 2022; pp. 47-74.
[27]
Matsuhama, M.; Saito, R.; Miyazaki, S. Development of a logic model for promoting incorporation of the concepts of impurity-related ICH guidelines into pharmacopoeias based on cause and effect analysis. Chem. Pharm. Bull., 2020, 68(11), 1034-1048.
[http://dx.doi.org/10.1248/cpb.c20-00380] [PMID: 33132370]
[28]
Geigert, J. Complex process-related impurity profiles. In: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals; Springer, 2023; pp. 339-379.
[29]
Shaikh, T.; Gosar, A. An overview and discussion of azido impurities and their risk assessments in drug substances and drug products. SSRN, , 4471358.2023
[30]
Holzgrabe, U. Nitrosated active pharmaceutical ingredients – lessons learned? J. Pharm. Sci., 2023, 112(5), 1210-1215.
[http://dx.doi.org/10.1016/j.xphs.2023.01.021] [PMID: 36720391]
[31]
Johnson, G.E.; Dobo, K.; Gollapudi, B.; Harvey, J.; Kenny, J.; Kenyon, M.; Lynch, A.; Minocherhomji, S.; Nicolette, J.; Thybaud, V.; Wheeldon, R.; Zeller, A. Permitted daily exposure limits for noteworthy N-nitrosamines. Environ. Mol. Mutagen., 2021, 62(5), 293-305.
[http://dx.doi.org/10.1002/em.22446] [PMID: 34089278]
[32]
Snodin, D.J.; Elder, D.P. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products. Regul. Toxicol. Pharmacol., 2019, 103, 325-329.
[http://dx.doi.org/10.1016/j.yrtph.2019.01.007] [PMID: 30629969]
[33]
Teasdale, A. Mutagenic impurities: Strategies for identification and control; John Wiley & Sons, 2022.
[34]
Joung, K.I.; Hwang, J.E.; Oh, I.S.; Cho, S.; Shin, J.Y. Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea. Sci. Rep., 2022, 12(1), 22396.
[http://dx.doi.org/10.1038/s41598-022-26691-0] [PMID: 36575247]
[35]
Teasdale, A. Mutagenic Impurities: Strategies for Identification and Control; John Wiley & Sons, Inc, 2021.
[http://dx.doi.org/10.1002/9781119551249]
[36]
Wichitnithad, W.; Nantaphol, S.; Noppakhunsomboon, K.; Rojsitthisak, P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharm. J., 2022.
[PMID: 36942272]
[37]
Dobo, K.L.; Kenyon, M.O.; Dirat, O.; Engel, M.; Fleetwood, A.; Martin, M.; Mattano, S.; Musso, A.; McWilliams, J.C.; Papanikolaou, A.; Parris, P.; Whritenour, J.; Yu, S.; Kalgutkar, A.S. Practical and science-based strategy for establishing acceptable intakes for drug product N-nitrosamine impurities. Chem. Res. Toxicol., 2022, 35(3), 475-489.
[http://dx.doi.org/10.1021/acs.chemrestox.1c00369] [PMID: 35212515]
[38]
Srinivasan, R.; Giridharan, J. Assessment of regulatory requirements for nitrosamine impurities on the drug development and post approval. Ann. Rom. Soc. Cell Biol., 2021, 25(7), 1633-1651.
[39]
Chandramore, M.A.; Chitte, S.S.; Patil, P.U.; Salunkhe, K.S.; Marathe, D.; Divekar, K.R. Regulatory aspects in assessment and control of DNA reactive (Mutagenic) impurities in API’s and final products to limit potential cancer risk as per ICH M7. J. Coast. Life Med., 2023, 11, 187-192.
[40]
Peryea, T.; Southall, N.; Miller, M.; Katzel, D.; Anderson, N.; Neyra, J.; Stemann, S.; Nguyễn, Ð.T.; Amugoda, D.; Newatia, A.; Ghazzaoui, R.; Johanson, E.; Diederik, H.; Callahan, L.; Switzer, F. Global substance registration system: Consistent scientific descriptions for substances related to health. Nucleic Acids Res., 2021, 49(D1), D1179-D1185.
[http://dx.doi.org/10.1093/nar/gkaa962] [PMID: 33137173]
[41]
Schlingemann, J.; Burns, M.J.; Ponting, D.J.; Martins Avila, C.; Romero, N.E.; Jaywant, M.A.; Smith, G.F.; Ashworth, I.W.; Simon, S.; Saal, C.; Wilk, A. The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J. Pharm. Sci., 2023, 112(5), 1287-1304.
[http://dx.doi.org/10.1016/j.xphs.2022.11.013] [PMID: 36402198]
[42]
Boetzel, R.; Schlingemann, J.; Hickert, S.; Korn, C.; Kocks, G.; Luck, B.; Blom, G.; Harrison, M.; François, M.; Allain, L.; Wu, Y.; Bousraf, Y. A nitrite excipient database: A useful tool to support N-nitrosamine risk assessments for drug products. J. Pharm. Sci., 2023, 112(6), 1615-1624.
[http://dx.doi.org/10.1016/j.xphs.2022.04.016] [PMID: 35500671]
[43]
Gushgari, A.J.; Halden, R.U. Critical review of major sources of human exposure to N-nitrosamines. Chemosphere, 2018, 210, 1124-1136.
[http://dx.doi.org/10.1016/j.chemosphere.2018.07.098] [PMID: 30208538]
[44]
Shaik, K.M.; Sarmah, B.; Wadekar, G.S.; Kumar, P. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques. Crit. Rev. Anal. Chem., 2022, 52(1), 53-71.
[http://dx.doi.org/10.1080/10408347.2020.1788375] [PMID: 32691615]
[45]
Kumar, M.; Shekhar, S.; Kumar, R.; Kumar, P.; Govarthanan, M.; Chaminda, T. Drinking water treatment and associated toxic byproducts: Concurrence and urgence. Environ. Pollut., 2023, 320, 121009.
[http://dx.doi.org/10.1016/j.envpol.2023.121009] [PMID: 36634860]
[46]
Nawrocki, J.; Andrzejewski, P. Nitrosamines and water. J. Hazard. Mater., 2011, 189(1-2), 1-18.
[http://dx.doi.org/10.1016/j.jhazmat.2011.02.005] [PMID: 21353742]
[47]
Prculovska, M.; Acevska, J.; Panovska, A.P.; Nakov, N.; Dimtirovska, A.; Brezovska, K. Root causes for presence of nitrosamine impurities in active pharmaceutical substances and finished pharmaceutical products; Macedonian Pharmaceutical Bulletin, 2022.
[http://dx.doi.org/10.33320/maced.pharm.bull.2022.68.03.025]
[48]
Dattatraya, J.P.; Arun, S.; Deshmukh, V.; Ghawate, V.; Pund, A. A review on nitrosamine impurities present in drugs. Pharm. Res., 2022, 4(2), 44-48.
[49]
Ali, R.; Babaahmadi, R.; Didsbury, M.; Stephens, R.; Melen, R.L.; Wirth, T. Flow electrochemistry for the N-Nitrosation of secondary amines. Chemistry, 2023, 29(32), e202300957.
[http://dx.doi.org/10.1002/chem.202300957] [PMID: 36975121]
[50]
Horne, S.; Vera, M.D.; Nagavelli, L.R.; Sayeed, V.A.; Heckman, L.; Johnson, D.; Berger, D.; Yip, Y.Y.; Krahn, C.L.; Sizukusa, L.O.; Rocha, N.F.M.; Bream, R.N.; Ludwig, J.; Keire, D.A.; Condran, G. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals. J. Pharm. Sci., 2023, 112(5), 1166-1182.
[http://dx.doi.org/10.1016/j.xphs.2022.12.022] [PMID: 36599405]
[51]
Yang, Q.; Sheng, M.; Huang, Y. Potential safety hazards associated with using N, N-dimethylformamide in chemical reactions. Org. Process Res. Dev., 2020, 24(9), 1586-1601.
[http://dx.doi.org/10.1021/acs.oprd.0c00330]
[52]
López-Rodríguez, R.; McManus, J.A.; Murphy, N.S.; Ott, M.A.; Burns, M.J. Pathways for N-nitroso compound formation: Secondary amines and beyond. Org. Process Res. Dev., 2020, 24(9), 1558-1585.
[http://dx.doi.org/10.1021/acs.oprd.0c00323]
[53]
Kalgutkar, A.S.; Driscoll, J.P. Is there enough evidence to classify cycloalkyl amine substituents as structural alerts? Biochem. Pharmacol., 2020, 174, 113796.
[http://dx.doi.org/10.1016/j.bcp.2020.113796] [PMID: 31926938]
[54]
Maundrell, N. Nitrosamine impurities: From raw materials to final drug product. Bioanalysis, 2022, 14(2), 63-66.
[http://dx.doi.org/10.4155/bio-2021-0238] [PMID: 34743592]
[55]
Schmidtsdorff, S.; Neumann, J.; Schmidt, A.H.; Parr, M.K. Risk assessment for nitrosated pharmaceuticals: A future perspective in drug development. Arch. Pharm., 2022, 355(4), 2100435.
[http://dx.doi.org/10.1002/ardp.202100435] [PMID: 35088435]
[56]
Dobariya, U.; Chauhan, N.; Patel, H.; Pardeshi, N. Nitrosamine impurities: Origin, control and regulatory recommendations. Int. J. Drug Regul., 2021, 9(2), 77-80.
[http://dx.doi.org/10.22270/ijdra.v9i2.472]
[57]
Masada, S.; Tsuji, G.; Arai, R.; Uchiyama, N.; Demizu, Y.; Tsutsumi, T.; Abe, Y.; Akiyama, H.; Hakamatsuka, T.; Izutsu, K.; Goda, Y.; Okuda, H. Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products. Sci. Rep., 2019, 9(1), 11852.
[http://dx.doi.org/10.1038/s41598-019-48344-5] [PMID: 31413326]
[58]
Mallavarapu, R.; Katari, N.K.; Siddhani, V.K.; Marisetti, V.M.; Rekulapally, V.K.; Vyas, G.; Jonnalagadda, S.B. Development and validation of rapid ultra high performance liquid chromatography with tandem mass spectroscopic method for the quantification of N-nitrosodimethyl amine and N-nitrosodiethyl amine in sitagliptin and metformin hydrochloride immediate and extended-release formulations. J. Sep. Sci., 2022, 45(16), 3067-3081.
[http://dx.doi.org/10.1002/jssc.202200226] [PMID: 35771715]
[59]
Cai, H.; Shen, C.; Xu, H.; Qian, H.; Pei, S.; Cai, P.; Song, J.; Zhang, Y. Seasonal variability, predictive modeling and health risks of N-nitrosamines in drinking water of Shanghai. Sci. Total Environ., 2023, 857(Pt 2), 159530.
[http://dx.doi.org/10.1016/j.scitotenv.2022.159530] [PMID: 36270378]
[60]
Milmo, S. Tackling serious impurities. Pharm. Technol., 2020, 44(8), 6.
[61]
Charoo, N.A.; Dharani, S.; Khan, M.A.; Rahman, Z. Nitroso impurities in drug products: An overview of risk assessment, regulatory milieu, and control strategy. AAPS PharmSciTech, 2023, 24(2), 60.
[http://dx.doi.org/10.1208/s12249-023-02523-w] [PMID: 36759424]
[62]
Akkaraju, H.; Tatia, R.; Mane, S.S.; Khade, A.B.; Dengale, S.J. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products. Regul. Toxicol. Pharmacol., 2023, 139, 105355.
[http://dx.doi.org/10.1016/j.yrtph.2023.105355] [PMID: 36792049]
[63]
Golob, N.; Peterlin, S.; Grahek, R.; Roškar, R. NDMA formation due to active ingredient degradation and nitrite traces in drug product. J. Pharm. Sci., 2023, 112(5), 1277-1286.
[http://dx.doi.org/10.1016/j.xphs.2023.03.007] [PMID: 36925105]
[64]
Tuesuwan, B.; Vongsutilers, V. Current threat of nitrosamines in pharmaceuticals and scientific strategies for risk mitigation. J. Pharm. Sci., 2023, 112(5), 1192-1209.
[http://dx.doi.org/10.1016/j.xphs.2023.01.028] [PMID: 36739905]
[65]
Harmon, P. Ranitidine: A proposed mechanistic rationale for NDMA formation and a potential control strategy. J. Pharm. Sci., 2023, 112(5), 1220-1224.
[http://dx.doi.org/10.1016/j.xphs.2022.11.011] [PMID: 36384193]
[66]
Dharani, S.; Mohamed, E.M.; Khuroo, T.; Ali, H.I.; Reddy, I.K.; Rahman, Z.; Khan, M.A. In-use stability assessment of FDA approved metformin immediate release and extended release products for N-Nitrosodimethylamine and dissolution quality attributes. Int. J. Pharm., 2022, 623, 121923.
[http://dx.doi.org/10.1016/j.ijpharm.2022.121923] [PMID: 35750279]
[67]
Jireš, J.; Douša, M.; Gibala, P.; Kubelka, T. N-Nitrosation in the absence of nitrosating agents in pharmaceuticals? J. Pharm. Biomed. Anal., 2022, 218, 114872.
[http://dx.doi.org/10.1016/j.jpba.2022.114872] [PMID: 35696937]
[68]
Aldawsari, F.S.; Alshehri, Y.M.; Alghamdi, T.S. N-nitrosodimethylamine (NDMA) contamination of ranitidine products: A review of recent findings. Yao Wu Shi Pin Fen Xi, 2021, 29(1), 39-45.
[http://dx.doi.org/10.38212/2224-6614.1133] [PMID: 35696227]
[69]
Jireš, J.; Kalášek, S.; Gibala, P.; Rudovský, J.; Douša, M.; Kubelka, T.; Hrubý, J.; Řezanka, P. Insight into the formation of N-nitrosodimethylamine in metformin products. J. Pharm. Biomed. Anal., 2021, 195, 113877.
[http://dx.doi.org/10.1016/j.jpba.2020.113877] [PMID: 33422831]
[70]
Begam, R.F.; Ravikumar, Y.; Velmurugan, R. Awareness about FDA announcement on voluntary recall of ranitidine among physicians and pharmacists in and around Chennai, India: A cross-sectional study. Futur. J. Pharm. Sci., 2021, 7(1), 112.
[http://dx.doi.org/10.1186/s43094-021-00267-7]
[71]
Gomm, W.; Röthlein, C.; Schüssel, K.; Brückner, G.; Schröder, H.; Heß, S.; Frötschl, R.; Broich, K.; Haenisch, B. N-nitrosodimethylamine-contaminated valsartan and the risk of cancer—a longitudinal cohort study based on german health insurance data. Dtsch. Arztebl. Int., 2021, 118(21), 357-362.
[PMID: 34247699]
[72]
Wichitnithad, W.; Nantaphol, S.; Thitikornpong, W.; Rojsitthisak, P. Development and validation of an LC-MS/MS method for simultaneous determination of three organic azido impurities in tetrazole-containing sartans. Arab. J. Chem., 2023, 16(8), 104951.
[http://dx.doi.org/10.1016/j.arabjc.2023.104951]
[73]
Thomas, R.; Tennant, R.E.; Oliveira, A.A.F.; Ponting, D.J. What makes a potent nitrosamine? Statistical validation of expert-derived structure–activity relationships. Chem. Res. Toxicol., 2022, 35(11), 1997-2013.
[http://dx.doi.org/10.1021/acs.chemrestox.2c00199] [PMID: 36302501]
[74]
Paglialunga, S.; van Haarst, A. The impact of N-nitrosamine impurities on clinical drug development. J. Pharm. Sci., 2023, 112(5), 1183-1191.
[http://dx.doi.org/10.1016/j.xphs.2023.01.017] [PMID: 36706834]
[75]
Shakleya, D.; Asmelash, B.; Alayoubi, A.; Abrigo, N.; Mohammad, A.; Wang, J.; Zhang, J.; Yang, J.; Marzan, T.A.; Li, D.; Shaklah, M.; Alsharif, F.M.; Desai, S.; Faustino, P.J.; Ashraf, M.; O’Connor, T.; Vera, M.; Raw, A.; Sayeed, V.A.; Keire, D. Bumetanide as a model NDSRI substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets. J. Pharm. Sci., 2023, 112(12), 3075-3087.
[http://dx.doi.org/10.1016/j.xphs.2023.06.013] [PMID: 37364772]

Rights & Permissions Print Cite
Article Metrics
30
2
© 2024 Bentham Science Publishers | Privacy Policy